Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

Lignende værker

• ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
  af: Bone, Henry G, et al.
  Udgivet: (2018)
• Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
  af: Leder, Benjamin Z, et al.
  Udgivet: (2019)
• Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
  af: Deal, Chad L., et al.
  Udgivet: (2019)
• Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial
  af: Watts, N.B., et al.
  Udgivet: (2020)
• Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
  af: Greenspan, Susan L., et al.
  Udgivet: (2020)